January 16, 2018
CBC is inviting new applications for the Catalyst Award program
One-time incentive awards (up to $250,000), focused on basic biological/biomedical or translational research, made to teams with principals and other strong representation from at least two of the CBC institutions.
If you plan to apply, please make sure that you are conforming to the MOST RECENT RFA revised Jan. 16, 2018. Applications not conforming to the specified guidelines will NOT be accepted.
Spring 2018 round submissions open at 8:00 AM on February 19, 2018 and close at 5:00 PM on February 23, 2018.
February 22, 2018
Fall 2017 Round Catalyst Awards Announced
The CBC is pleased to announce that three teams received Catalyst Awards in Fall 2017 application round:
PIs: Yamuna Krishnan (UChicago) and Dimitri Krainc (NU) for the project: In situ Lysosomal Ion Imaging as a Sensitive Diagnostic for Lysosomal Disorders
PIs: Raymond Moellering (UChicago) and Sarki Abdulkadir (NU) for the project: Defining Prostate Tumor Malignancy with Activity-Dependent Pet Probes
PIs: Xiaojing Yang (UIC) and Minglei Zhao (UChicago) for the project: Observing Protein Allostery Dynamics by Single-Particle Imaging
February 22, 2018
What causes one disease may cure another—two NU scientists and CBC community members, Marcus Peter and Shad Thaxton, collaborate to develop a potent cancer treatment
Marcus Peter and Shad Thaxton, NU, are senior authors on a recent publication in EMBO Reports, that describes how small interfering RNAs (siRNAs) with high homology to the trinucleotide repeat expansions of the huntingtin gene (responsible for Huntington’s disease), are highly toxic to cancer cells both in culture and in animal models. The authors suggest that such siRNAs could be exploited to develop novel anti-cancer reagents. Both scientists have links to CBC: Peter was an invited speaker at a 2013 CBC Exploratory Workshop, focused to ovarian cancer. Thaxton and a postdoc in his lab, Linda Foid, received a 2014 CBC Postdoctoral Research Award. Congratulations!
February 14, 2018
Tricking bacteria to remain non-hostile may become a method of choice in preventive medicine—the Federle lab at UIC shows how
A recent publication from the Federle lab, UIC, published in the Journal of Biological Chemistry, describes a novel compound able to induce quorum sensing (QS)—the process of regulation of gene expression in response to fluctuations in bacteria density. Learning how to perturb QS in a density-independent way presents an intriguing possibility of regulating bacterial virulence. The study is partially attributed to CBC funding via a CBC High-throughput Screening Award (2015) to Michael Federle (UIC) and Tiara Pérez Morales (currently at Benedictine University). Pérez Morales is first, and Federle senior author on the paper. Kiira Ratia, UIC is one of the co-authors. Federle and Ratia have many additional links to CBC (see the article). Congratulations to all involved in the study!
February 13, 2018
What do we mean by ‘discharging translational risk’?
Decision-making in biotech and pharma is often governed through an analysis of risk (and reward) and much of my prior career has been focused on management of varying aspects of risk. How to best identify risk, how to balance it against potential reward, how to allocate it across a portfolio of programs/assets, and importantly how to ‘discharge it’ systematically and efficiently. In drafting the initial RFA for the CBC’s new Phase 2 translationally focused program, the Accelerator Award, I found that my colleagues liked the concept, but often found it somewhat poorly defined…
April 25-26, 2018
UChicago Computation Institute
GlobusWorld 2018: Connecting your Research Universe
May 10, 2018
NU Cognitive Neurology and Alzheimer’s Disease Center
24th Annual Alzheimer Day
February 20, 2018
SmartHealth Activator & Rosalind Franklin University of Medicine and Science
BioPathways Entrepreneurial Speaker Series
February 21, 2018
Women in Bio (WIB) – Chicago
A Discussion of the Legal, Regulatory, and Business Concerns for Biosimilars in 2018
Women in Bio (WIB) Chicago is hosting A Discussion of the Legal, Regulatory, and Business Concerns for Biosimilars in 2018. Last year was a big one in the world of biosimilars: from doubling the number of approved biosimilar products to obtaining clarity on the legal landscape. Our distinguished panel will discuss the myriad legal, regulatory, scientific, pricing, and access issues that biosimilar applicants will be facing this year–issues which will determine whether the public will see another banner year for the availability of life- and cost-saving drug therapies. The panel will include Rekha Hanu, Executive Director, Chief IP Counsel, Akorn Pharmaceuticals and Chistine Simmon, Senior Vice President, Policy & Strategic Alliances, Association for Medicines.